Insmed financials
$115.63−1.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M | $164.4M | $136.5M | $9.8M | $0.00 | $0.00 |
| Gross profit | $483.5M | $278.0M | $239.6M | $190.2M | $144.3M | $124.5M | $112.3M | $7.4M | $0.00 | $0.00 |
| Gross margin | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | 75.7% | 82.3% | 75.4% | — | — |
| Operating income | -$1.25B | -$878.3M | -$709.6M | -$457.3M | -$375.1M | -$265.2M | -$235.2M | -$307.3M | -$188.9M | -$173.4M |
| Net income | -$1.28B | -$913.8M | -$749.6M | -$481.5M | -$434.7M | -$294.1M | -$254.3M | -$324.3M | -$192.6M | -$176.3M |
| Net margin | −210.5% | −251.2% | −245.6% | −196.3% | −230.6% | −178.9% | −186.4% | −3297.2% | — | — |
| Diluted EPS | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 |
| EBITDA | -$1.23B | -$867.2M | -$699.0M | -$465.8M | -$352.5M | -$250.0M | -$224.7M | -$302.5M | -$186.0M | -$171.0M |
| Operating cash flow | -$935.0M | -$683.9M | -$536.2M | -$400.4M | -$370.6M | -$219.3M | -$250.6M | -$258.0M | -$159.6M | -$146.7M |
| Free cash flow | -$967.6M | -$705.8M | -$549.5M | -$410.3M | -$377.9M | -$225.6M | -$292.9M | -$271.1M | -$162.6M | -$150.9M |
| Diluted shares | 199.0M | 164.0M | 140.4M | 123.0M | 112.1M | 97.6M | 84.6M | 76.9M | 66.6M | 61.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $510.4M | $555.0M | $482.4M | $1.07B | $716.8M | $532.8M |
| Short-term investments | $919.6M | $878.8M | $298.1M | $74.2M | $0.00 | — |
| Total debt | $565.0M | $1.13B | $1.18B | $1.16B | $580.7M | $371.0M |
| Total assets | $2.26B | $2.03B | $1.33B | $1.66B | $1.24B | $796.2M |
| Total liabilities | $1.53B | $1.74B | $1.66B | $1.57B | $833.0M | $520.3M |
| Shareholders' equity | $739.0M | $285.4M | -$331.9M | $88.0M | $410.5M | $275.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology